AC Immune

A Swiss biopharmaceutical company developing innovative therapeutics for the treatment of Alzheimer's disease including vaccines, antibodies and small molecules, leveraging therapeutic molecules for diagnostic use. Since its foundation in 2003, the company has raised CHF 24 million in two financing rounds. At the end of 2006, it reached a more than US$ 300 million out-licensing agreement with Genentech.